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Background: When treating cerebral metastases all involved multidisciplinary oncological specialists have to
cooperate closely to provide the best care for these patients. For the resection of brain metastasis several
studies reported a considerable risk of new postoperative paresis. Pre- and perioperative chemotherapy (Ctx) or
radiotherapy (Rtx) alter vasculature and adjacent fiber tracts on the one hand, and many patients already present
with paresis prior to surgery on the other hand. As such factors were repeatedly considered risk factors for
perioperative complications, we designed this study to also identify risk factors for brain metastases resection.
Methods: Between 2006 and 2011, we resected 206 brain metastases consecutively, 56 in eloquent motor areas
and 150 in non-eloquent ones. We evaluated the influences of preoperative paresis, previous Rtx or Ctx as well as
recursive partitioning analysis (RPA) class on postoperative outcome.
Results: In general, 8.7% of all patients postoperatively developed a new permanent paresis. In contrast to
preoperative Ctx, previous Rtx as a single or combined treatment strategy was a significant risk factor for
postoperative motor weakness. This risk was even increased in perirolandic and rolandic lesions. Our data show
significantly increased risk of new deficits for patients assigned to RPA class 3. Even in non-eloquently located brain
metastases the risk of new postoperative paresis has not to be underestimated. Despite the microsurgical approach,
our cohort shows a high rate of unexpected residual tumors in postoperative MRI, which supports recent data on
brain metastases’ infiltrative nature but might also be the result of our strict study protocol.
Conclusions: Surgical resection is a safe treatment of brain metastases. However, preoperative Rtx and RPA score 3
have to be taken into account when surgical resection is considered.
Keywords: Cerebral metastases, Intraoperative neurophysiological monitoring, Motor evoked potentials,
Neurological deficitBackground
Today, treatment of cerebral metastases is a topic, which
concerns many specialties and an interdisciplinary onco-
logical cooperation is crucial to provide the best care for
these patients. Modern treatment options for cerebral
metastases limit surgical treatment to a subgroup of pa-
tients, which present with symptomatic lesions such as
rolandic or cerebellar metastases. Both radiosurgery and
surgical resection have been shown to have comparable
rates of local control. By contrast, whole brain radiation
therapy (WBRT) alone without surgery or radiosurgery
led to significantly shorter survival and local control* Correspondence: Sandro.Krieg@lrz.tum.de
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article, unless otherwise stated.[1,2]. Nonetheless, many patients with supratentorial
metastases show a focal deficit due to focal mass ef-
fects. These patients are especially eligible for surgical
resection to facilitate early recovery from neurological
deficits [3]. Thus, surgical resection frequently treats me-
tastases within or close to the motor cortex or corticos-
pinal tract (CST).
Just recently, there are some hints that cerebral metas-
tases infiltrate surrounding brain tissue, which might
change the surgical and radiosurgical approach [4,5].
Moreover, the medical and surgical community must
discuss postoperative impairment of the motor system
to properly select patients for surgical resection and
to increase awareness of postoperative motor deficitsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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is infiltrated [2,6,7].
This study aims to identify risk factors for patients
with brain metastases undergoing surgical resection, to
raise awareness of those factors and encourage the
proper selection of patients for surgical treatment.
Methods
Patient cohort
Between 2006 and 2011 206 patients underwent resec-
tion of brain metastases. An interdisciplinary tumor board
discussed every case prior to surgery, and surgery required
the consent of all disciplines (neurooncology, neurosur-
gery, medical oncology, and radiation oncology) with re-
gard to the present treatment guidelines [8,9]. This board
frequently recommended surgical resection, especially for
patients with disabling motor weakness, increased edema
formation, cystic metastases, or metastases resistant to
radio- or chemotherapy.
These were 56 metastases in eloquent motor areas (in
or directly adjacent to the rolandic cortex or CST) using
intraoperative neurophysiological monitoring (IOM) by
monopolar direct cortical stimulation for motor evoked
potentials (MEPs) and 150 patients with metastases in
non-eloquent brain regions in terms of motor function
(all others), which underwent surgery without IOM.
Figure 1 shows examples of the evaluated motor elo-
quent lesions. We determined eligibility for IOM based on
the topographic association between metastases and CST
or preoperative magnetic resonance imaging (MRI) of the
primary motor cortex.
Standardized patient evaluation
Prior to surgery, all patients underwent MRI for tumor
diagnosis, localization, and acquisition of a navigationalFigure 1 Illustrative cases. Examples of motor eloquently localized metas
metastases in the middle frontal lobe (B) as evaluated in this study. We alsdataset for intraoperative neuronavigation (BrainLAB Vec-
tor Vision Sky, BrainLAB Vector Vision 2® or BrainLAB
Curve®, Feldkirchen, Germany) (Figure 1). All patients
underwent preoperative neurological evaluation of sensory
function, muscle strength, coordination, and cranial nerve
function. Each patient also received a recursive partition-
ing analysis (RPA) classification [10]. This score assigns
patients with cerebral metastases to 3 classes:
Class 1: Karnofsky Performance Score (KPS) ≥70,
age <65 years, controlled primary tumor, no
extracranial metastases
Class 2: KPS ≥70 but not all of the above features
Class 3: KPS <70 [10].
All patients again underwent neurological assessment
directly after anesthesia and daily from the first posto-
perative day until discharge. Routine follow-up included
neurological assessment at 6–8 weeks postoperatively,
and every 3 months on a regular basis.
Every patient who presented with a new paresis dir-
ectly after surgery underwent an immediate cranial ima-
ging to exclude secondary hemorrhage or ischemia,
an MRI scan within 48 hours after resection to assess
tumor removal, edema formation, and hemorrhage. Re-
sidual tumor was defined as any suspected contrast en-
hancement in the resection cavity on the MRI scan within
48 hours after surgery. The MRI protocol also included
diffusion images to detect potential ischemia. Routine
follow-up included MRI scans every 3 months, depen-
ding on concurrent oncological therapy and tumor
entity. We also reviewed these follow-up MRI scans for
recurrent metastases, since neurological status during
follow-up was only considered during progression-free
survival.tases in the precentral (A) and non-motor-eloquently localized
o measure tumor diameter (B).
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differentiated between permanent and temporary deficit.
A new permanent paresis was defined as a new or aggra-
vated motor deficit due to surgery that did not return to
the preoperative status during follow-up. A temporary
deficit was present when a new or aggravated postopera-
tive paresis resolved at least during the regular 8-week
follow-up interval. A motor deficit was defined as any
impairment of motor performance even if the patient
only presented with deteriorated fine motor skills of the
small hand muscles.Surgical procedure
In general, we used total intravenous anesthesia (TIVA),
and strictly avoided volatile anesthetics because of their
interference with IOM [11-13]. Propofol and remifenta-
nyl were continuously administered for intraoperative
anesthesia and analgesia. We used the neuromuscular
blocker rocuronium for intubation only and not dur-
ing surgery.
As reported earlier, we used IOM by MEP monitoring
in 56 cases, when tumor location was supposed to be
close to the rolandic cortex or CST on axial slices of the
preoperative MRI scans [3].
During resection, an amplitude decline of 50% or more
of the baseline was considered a substantial decline. The
surgeon reversed the causal surgical step when appli-
cable, such as by removing spatulas, and irrigated the
exposed brain with warm Ringer’s solution. When the
tumor resection was close to major blood vessels, we
irrigated the resection cavity with nimodipine to reverse
or avoid vasospasm. In most cases, after stabilization or
renormalization of MEPs, tumor resection proceeded [3].Ethical standard
The study is well in accordance with the ethical stan-
dards of the Technical University of Munich, the local
ethics committee (registration number: 2826/10), and
the Declaration of Helsinki.Statistical analysis
We performed a Chi-square test or Fisher’s exact test on
the distribution of several attributes. Several tests yielded
differences between two groups: the Mann–Whitney-
Wilcoxon test, using multiple comparisons on ranks for
independent samples, the Kruskall-Wallis test for non-
parametric one-way analysis of variance (ANOVA), and
Dunn’s test as the post hoc test. All results are presented
as mean ± standard deviation (SD). We also calculated
median and range (GraphPad Prism 5.0c, La Jolla, CA,
USA); p < 0.05 was considered significant.Results
Out of 206 enrolled patients, 56 suffered from motor
eloquent brain metastases and 150 from non-eloquently
located lesions in terms of motor function. Details
specific to preoperative status are shown in Table 1. The
presence of motor eloquence had no statistically signifi-
cant impact upon survival (Figure 2).Postoperative results
Motor eloquent tumor location
Out of the 56 patients with metastases in motor elo-
quent locations, 12 (21.4%) showed aggravated paresis
after surgery, which remained permanent in seven (12.5%)
and resolved during follow-up in 5 patients (8.9%)
(Figure 3A). Among those seven with permanent def-
icits, four suffered from secondary hemorrhage, and
three from ischemia. Moreover, postoperative MRIs
on the five patients with temporary deficits revealed one
case of ischemia and another two involving the supple-
mentary motor area (SMA).
Thirteen patients (23.2%) improved after surgery.
During the operation, the surgeon expected gross total
resection (GTR) in 92.5% of cases and subtotal resection
(STR) in 7.5%. However, postoperative MRI were searched
for contrast enhancement and showed GTR in 72.0%,
leaving an unexpected residual (UR) of 20.5%; at least
according to the strict protocol of this study.
Cases with GTR had a mean survival of 10.6 months ±
8.9 months, in contrast to cases with STR 6.1 months ±
5.7 months (p = 0.31; Figure 3B). The mean survival after
surgery was 8.3 ± 7.1 months (range 0.1-23.0 months).Non-motor-eloquent tumor location
In general, 11 patients (7.0%) suffered from a permanent
and six patients (4.3%) from temporary paresis in the non-
motor-eloquent group. Among 11 patients with perma-
nent deficits, one suffered from secondary hemorrhage
and another from ischemia after surgery. Moreover,
among the six with temporary increased paresis, one
suffered from secondary hemorrhage and also under-
went surgical revision.
Out of 150 patients, 27 (18.2%) showed improvement
of their preoperative motor deficit (Figure 3A). During
the operation, the surgeon expected GTR in 131 cases
(89.3%) and STR in 15 cases (10.7%). We gathered post-
operative MRI data in 117 cases, which showed GTR in
78 cases (66.7%) and STR in 39 cases (33.3%) according
to our considerably strict study guidelines. Thus, an UR
was present in 26 cases (22.6%). For the remaining
manuscript, GTR is defined as MRI-confirmed GTR.
After GTR, overall survival was 9.1 ± 6.9 months and
7.5 ± 7.5 months after STR (p = 0.08). Concerning all pa-
tients harboring non-motor-eloquent metastases, the mean
Table 1 Patient characteristics
Eloquent Non-eloquent
Number of patients 56 150
Preoperative paresis 57.0% 47.3%
Sex Male 32 (57.0%) 72 (48.0%)
Female 24 (43.0%) 78 (52.0%)
Median age ± SD 61.4 ± 13.1 years 60.9 ± 11.9 years




















Paranasial sinus 1.8% 0.7%
Urothelial 1.8% 0.7%
SCLC 1.8% 2.0%
Uterine sarcoma 1.8% 0.7%
Gastric - 1.3%
Larynx - 1.3%
Gall bladder - 0.7%








RPA score 1 14.0% 15.0%
2 64.0% 65.0%
3 22.0% 20.0%
Preoperative therapy Rtx 5.4% 2.7%
(n = 150) Ctx 30.4% 34.0%
Rtx + Ctx 14.3% 19.3%
Overview of all enrolled patients including sex, preoperative existing deficit,
primary tumor, and preoperative therapy). Ctx, Chemotherapy; CUP, Carcinoma
of unknown primary; NSCLC, Non small cell lung cancer; RCC, Renal cell cancer;
Rtx, radiotherapy; SCLC, Small cell lung cancer; SD, Standard deviation.
Obermueller et al. BMC Cancer 2014, 14:21 Page 4 of 10
http://www.biomedcentral.com/1471-2407/14/21survival was 7.9 ± 8.2 months (range 0.5-47.0 months) after
surgery (Figure 3B).
Histology and tumor location vs. new postoperative deficit
Type of primary tumor bore no significant relation to
postoperative incidence of temporary or permanent im-
pairment of motor function (data not shown). In the
motor eloquent group, proximity to the rolandic cortex
showed a trend to be associated with postoperative par-
esis (p = 0.101). Surgery of frontal cortex lesions anterior
to the precentral gyrus never caused deficits, even in the
insula, whereas resection within the precentral cortex
had the strongest association with permanent deficits
(23.5%).
The non-motor-eloquently located group presented a
wide variety of locations, and postoperative motor de-
ficits were far less frequent in regions far away from
the motor cortex or CST (p < 0.05; Figure 4). However,
three patients showed permanent new paresis despite
temporal tumor location. One of these patients suffered
secondary hemorrhage, and one with temporodorsal
metastasis presented with new ischemia within lateral
parts of the CST.
RPA class
In the motor eloquent group, two patients (25.0%) of
RPA class 1, five patients (13.9%) of class 2, and five
patients (45.5%) of class 3 suffered new postoperative pa-
resis (p < 0.05, Figure 5A). In patients with non-motor-
eloquently located brain metastases, three patients (13.6%)
of class 1, 10 patients (10.3%) of class 2, and 12 patients
(41.4%) of class 3 showed a new postoperative paresis
(p < 0.001; Figure 5B). However, there was no difference
between motor eloquent and non-eloquent tumor loca-
tion. Table 2 shows the results of the relation between
RPA class and overall survival.
Preoperative vs. postoperative deficit
Regarding the rate of preoperative motor deficits and
their effect on outcome, we found comparable results in
both groups. Improvements emerged in 31.0% of the
eloquent group and 38.0% in the non-eloquent group.
Immediately after surgery, 13.0% of patients in the mo-
tor eloquent group with preoperative paresis deteriora-
ted, compared to 21.0% in the motor eloquent group
without preoperative paresis. In the non-eloquent group,
we found deterioration in 20.0% with preoperative deficit
and 14.0% without it (Figure 6A). Even in the follow-up,
there was no significant difference between preoperative
apparent and new postoperative deficit (Figure 6B).
Preoperative therapy
Because some patients had received different treat-
ments prior to surgery, we investigated the relation of
Figure 2 Survival. Kaplan-Meier survival analysis of motor eloquently and non-eloquently located brain metastases.
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motor eloquent group, 55% of patients who had had
radiotherapy of the brain (Rtx) developed a new post-
operative deficit, whereas patients who had had no
Rtx developed it in only 13.0% of cases (p = 0.01;
Figure 7A). In the non-motor-eloquent group, treat-
ment with Rtx preceded a new deficit in 28.1% of
cases, and no such treatment preceded it in 14.0% of
cases (p < 0.05; Figure 7B). Preoperative chemotherapy
(Ctx) had no significant effect on postoperative out-
come. In motor eloquently located metastases, the
occurrence of a new paresis was 24.0% with Ctx and
19.4% without it. In patients with non-motor-eloquently
located metastases, 18.8% with and 14.7% without Ctx
presented new pareses.
Table 3 represents the different preoperative strategies
of all enrolled patients. Both groups showed statisticallyFigure 3 Clinical course. A: Columns showing the relation of motor eloqu
survival in months with resection in postoperative MRI.significant correlation between preoperative treatment
and new postoperative paresis (motor eloquent: p = 0.012;
non-eloquent p = 0.045).
Discussion
Outcome after brain metastasis surgery
Among all 206 patients, 39 (19.0%) improved their neu-
rological status postoperatively, whereas 29 (14.0%) de-
veloped a new postoperative deficit. The number of
deficits is comparable to that of other published stu-
dies which reported neurological deterioration in 6%
(RPA score 1 and 2) and 19% (RPA score 3) of patients
[4,14], even to stereotactic radiosurgical investigations
[15,16]. We examined every patient meticulously and
even mild deficits were taken account. The incidence of
postoperative permanent deficit in the motor eloquently
located group was higher than in the non-eloquent groupence of tumor and pre- and postoperative status. B: Correlation of
Figure 4 Tumor location. Columns represent the distribution of postoperative outcome in relation to metastasis location in motor eloquent
(A) and non-eloquent (B) metastases. A trend towards postoperative deficits in eloquently located lesions is shown without reaching statistical
significance (p = 0.101).
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cortex or subcortical motor tracts [3]. Surgery is compar-
able to radiosurgery in terms of local control and survival
and still plays an indispensable role in the treatment of
brain metastases [4,17,18].
Analysis of postoperative MRI
Residual tumor
The residual measured in the postoperative MRI was
about 20%, with a slight trend towards less residual in
monitored patients. Use of IOM could explain this trend.
Neurosurgeons have always considered a metastasis as a
tumor with sharp borders. But recent studies provided
some data that metastases instead might have an infiltra-
tive growth pattern [4,19]. Our results of an unexpected
residual of about 20% lead into the same direction, but we
have to keep in mind that the definition of residual tumor
presented by residual contrast enhancement can result in
considerable overestimation of real UR due to reactive
postoperative changes. We performed postoperative MRIsFigure 5 Recursive partitioning analysis. There was significant correlatio
(A): p < 0.05; non-eloquent (B): p < 0.001).on 124 out of 150 patients in the non-eloquent group
(82.6%), and 50 out of 56 patients in the motor elo-
quent group (89.0%). Lee et al. reported significant diffe-
rence in survival between GTR (20.4 months) and STR
(15.1 months)[18]. However, since that study included
only patients initially treated by surgery, the results cannot
be compared to our cohort.
As other studies have stated, tumor residual can lead
to higher local recurrence rate and shorter survival.
These studies improved the clinical outcome by perfor-
ming supramarginal resections of metastases, even if elo-
quently located [4,5]. In the non-motor-eloquent group,
a trend toward longer survival without tumor residual
was shown (Figure 3B). In the motor eloquent group,
that trend was even larger, but did not reach statistical
significance (eloquent: p = 0.31; non-eloquent: p = 0.08).
This might be due to different adjuvant strategies in
individual patients and small sample size.
However, combining our results with the cited pre-
vious data, we have to consider whether intraoperativen between the RPA class and new postoperative deficit (eloquent





1 9.9 ± 5.6 9,2 ± 5.9
2 9.1 ± 6.8 8.7 ± 7.7
3 4.8 ± 8.4 5.6 ± 9.7
p-value 0.411 0.279
Despite missing statistical significance (p = 0.41 and p = 0.28) a trend is shown
towards a prolonged survival in RPA class 1 and 2 for all patients.
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care as both means should improve the rate of GTR and
therefore survival.Figure 7 Preoperative radiotherapy. There is a significant
difference in the occurrence of new postoperative deficits between
patients treated by preoperative radiotherapy (Rtx) and patients who
do not receive such treatment, in motor eloquent and non-eloquently
located metastases.Histology and tumor location
We found the type of primary tumor did not help pre-
dict new postoperative paresis or survival. Lagerwaard
et al. described it as predictive of survival in their ana-
lysis of 1292 patients [20]. Hall et al.’s study of 740 pa-
tients also showed patients suffering ovarian cancer had
the highest survival rate, small cell lung cancer patients
the lowest [21]. Thus, it seems likely that our cohort is
too small to show statistical significance in this matter.
However, our results confirm relation between pro-
ximity to the motor cortex and a considerably high risk
of new postoperative motor deficit (Figure 4). Our num-
ber of postoperative deficits is high, partly because theFigure 6 Motor status. A: Change in motor function after surgery in relat
status during follow-up. There was no significant relation between A and Bstandardized neurological evaluation of our patients
defines even minor weakness as new paresis.
In the motor eloquent group, four patients suffered
secondary hemorrhages causing permanent motor defi-
cits. Ischemia only occurred in one case. When opera-
ting especially near or within the rolandic cortex, our
department rarely uses the bipolar cautery, to avoid con-
secutive ischemia.ion to the preoperative neurological status. B: Course of neurological
in either group.
Table 3 Preoperative therapy
Rtx Ctx Rtx + Ctx No preoperative therapy p
Eloquent New deficit 33.3% 5.9% 63.0% 17.8% 0.012
No new deficit 66.6% 93.1% 37.0% 82.2%
Non-eloquent New deficit 0.0% 8.9% 33.3% 12.5% 0.045
No new deficit 100% 91.1% 66.6% 87.5%
All types of preoperative therapy had a significant effect on new postoperative deficits in the eloquent group (p = 0.012) and the non-eloquent group (p = 0.045).
Rtx, Radiotherapy; Ctx, Chemotherapy.
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cases of new permanent motor deficits (1.3%) after
surgery due to ischemia and secondary hemorrhage.
This tells us that even such tumors carry the risk of
postoperative paresis, and we have to bear this fact in
mind when we counsel our patients.
RPA class vs. outcome
Patients in RPA class 3 had a significantly higher risk of
new postoperative deficits (Figure 5). Besides the prog-
nosis of survival, we can get information about the post-
operative outcome. The most relevant factor in the RPA
class system is the KPS. Patients were assigned to class 3
if they have a KPS below 70, regardless of other factors.
In 2007, Eichler et al. recommended a KPS above 70 for
surgical treatment [22].
The group of Schödel et al. investigated the impact of
surgical resection on neurological outcome in 206 pa-
tients [23]. Poor RPA class was also detected as an inde-
pendent indicator of shorter survival, but nevertheless,
surgery can improve neurological status significantly in
these cases, as our data clearly shows (Figure 3). Concer-
ning patients after Rtx, Gaspar et al. investigated 1200
patients, and, in another study, 445 patients, and repor-
ted a significant difference in survival of 2.3 months in
class 3, 4.2 months in class 2 and 7.1 months in class 1
[10,24]. Due to our small number of patients we failed
to show statistical significance, but we did show a longer
survival rate in surgically treated patients, as well as a
trend towards longer survival in lower RPA classes
(Table 2). Schackert et al. also described RPA class 1 as a
favorable factor for prolonged postoperative survival,
along with other factors such as a small number of
metastases and adjuvant Rtx [25]. As a consequence, the
RPA score can be a useful tool when considering indica-
tions for surgery.
Preoperative vs. postoperative deficit
Only 8.0% in the motor eloquent and 10.3% in the non-
motor-eloquent group with preoperative deficits suffered
permanent deficit (Figure 6B). The neurological status
worsened after surgery in only 17.0% of all patients.
When Walter et al. treated metastases in the central
region in 20 patients, incidence of postoperative paresiswas 15.0% [26]. Paek et al. investigated 208 patients with
motor eloquently located metastases, and only 8.0% wors-
ened postoperatively in their KPS but 6 to 19% showed
a new surgery-related permanent neurological deficit
[14]. Note that even new minor motor deficits can be
assigned to the same KPS as preoperatively. In motor
eloquently located gliomas, several studies showed simi-
lar results [27-29].
Different treatment strategies vs. new postoperative deficit
Figure 7 emphasizes the significant role of previous Rtx
leading to significantly higher risk for new postoperative
motor deficits in patients with motor eloquently located
brain metastases (p = 0.0116). By contrast, Ctx seems to
have no impact on this.
In the motor eloquent group and non-motor-eloquent
group we found a significant relation between performed
preoperative treatment strategies (p = 0.0122 vs. 0.045).
Despite the small number of patients, we can claim that
Rtx, alone or in combination with Ctx, increases the risk
of new postoperative deficits, especially in motor elo-
quent metastases (Figure 7). Nevertheless, surgery can
be a useful tool, especially in cases of symptomatic mass
effect [30,31]. In these cases, IOM can minimize risk of
postoperative deficits [3].
Limitations
The number of enrolled patients is still small in some
subgroups, and in some cases — for instance, the
relation between RPA class and survival — may have
cost the study statistical significance. The retrospective
analysis of our data is another major limitation.
Conclusions
Surgical resection of brain metastases is a safe procedure
despite still harboring considerable risks for the patients.
But some factors influence the postoperative outcome
more than expected. Preoperative Rtx, motor eloquent
tumor location, and RPA class play a significant role in
the likelihood of new postoperative motor deficits. Thus,
on the basis of this study, indication for surgical resec-
tion has to be considered carefully in these subgroups
and discussed carefully in interdisciplinary oncological
conferences.
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